- Home
- TKLF vs MBRX Comparison
TKLF vs MBRX Comparison
Compare TKLF & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKLF
- MBRX
- Stock Information
- Founded
- TKLF 2006
- MBRX 2015
- Country
- TKLF Japan
- MBRX United States
- Employees
- TKLF N/A
- MBRX N/A
- Industry
- TKLF Other Specialty Stores
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- TKLF Consumer Discretionary
- MBRX Health Care
- Exchange
- TKLF Nasdaq
- MBRX Nasdaq
- Market Cap
- TKLF 16.0M
- MBRX 12.9M
- IPO Year
- TKLF 2022
- MBRX 2016
- Fundamental
- Price
- TKLF $3.56
- MBRX $0.31
- Analyst Decision
- TKLF
- MBRX Strong Buy
- Analyst Count
- TKLF 0
- MBRX 3
- Target Price
- TKLF N/A
- MBRX $5.33
- AVG Volume (30 Days)
- TKLF 10.6K
- MBRX 5.2M
- Earning Date
- TKLF 07-15-2025
- MBRX 08-13-2025
- Dividend Yield
- TKLF N/A
- MBRX N/A
- EPS Growth
- TKLF N/A
- MBRX N/A
- EPS
- TKLF 1.70
- MBRX N/A
- Revenue
- TKLF $219,520,631.00
- MBRX N/A
- Revenue This Year
- TKLF N/A
- MBRX N/A
- Revenue Next Year
- TKLF N/A
- MBRX N/A
- P/E Ratio
- TKLF $2.18
- MBRX N/A
- Revenue Growth
- TKLF 32.02
- MBRX N/A
- 52 Week Low
- TKLF $2.20
- MBRX $0.25
- 52 Week High
- TKLF $8.53
- MBRX $4.71
- Technical
- Relative Strength Index (RSI)
- TKLF 51.46
- MBRX 24.39
- Support Level
- TKLF $3.20
- MBRX $0.25
- Resistance Level
- TKLF $3.85
- MBRX $0.42
- Average True Range (ATR)
- TKLF 0.20
- MBRX 0.06
- MACD
- TKLF -0.02
- MBRX -0.03
- Stochastic Oscillator
- TKLF 60.93
- MBRX 13.07
About TKLF Yoshitsu Co. Ltd
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores; Online Stores and Services; and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from China followed by Japan and other overseas markets.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.